

Optimized Protocol is the Key for Clinical Use of Stem Cell Therapy in Stroke

Mohammad Hossein Khorraminejad Shirazi and Seyed Mojtaba Hosseini*

Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding author: Seyed Mojtaba Hosseini, Cell and Molecular Medicine, Student Research Group, Medical School, Shiraz university of Medical Sciences, Shiraz, Iran, Tel: +989178033070; Fax: +987132122970; E-mail: Hosseini2010m@gmail.com

Rec date: Jan 26, 2016; Acc date: Mar 01, 2016; Pub date: Mar 06, 2016

Copyright: © 2016 Khorraminejad Shirazi MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Perspective

Stroke is the second cause of mortality in industrial countries after ischemic heart disease [1]. Ischemic stroke results from an artery occlusion and leads to oxygen and glucose shortage in brain [2]. Cerebral ischemia results in inflammation and oxidative stress leading to neuronal loss and brain damage [3,4]. To these days, rt-PA is the only approved drug for stroke; however, increasing the risk of bleeding and golden time limitation are the problems associated with rt-PA [5].

Stem cell therapy is believed to be useful for treating neurodegenerative diseases including stroke. Mesenchymal stem cells (MSCs) have beneficial effects including anti-inflammatory effects, anti-apoptotic effects and their role in protection against oxidative stress [6,7]. Several characteristics of neural stem cells (NSCs) have made them suitable for stem cell therapy including promotion of angiogenesis and neurogenesis after cerebral ischemia [8], anti-apoptotic and immunomodulatory effects [9-17]. Most importantly, NSCs could promote regeneration due to their ability to differentiate into three neural lineage cells that are neurons, oligodendrocytes and astrocytes [18,19]. By using combination stem cell therapy we take advantage of both MSCs and NSCs and we would get better results for treating cerebral ischemia. To promote the outcome after combination stem cell therapy, we should optimize its protocol. For this purpose, we found the optimum time for using MSCs and NSCs. The optimum time for injecting MSCs is 12 hours after cerebral ischemia and the optimum for NSCs is 3 days. Administration of MSCs in acute phase (12 hours) makes the microenvironment suitable for NSCs transplantation in sub-acute phase (3 days) after cerebral ischemia [20,21].

Stroke leads to astrogliosis and formation of glial scars by increasing the expression of GFAP that can inhibit regeneration [22-26]. Although NSCs have numerous positive effects for stem cell therapy, they increase astrogliosis [27]. Astrocytes secrete inflammatory cytokines [28]; therefore, they might be an obstacle for achieving the optimum effect of NSCs transplantation. By omitting the astrocytes, the efficacy of NSCs transplantation would be increased [29].

Conclusion

In spite of several improvements in combination stem cell therapy protocol, several challenges still remain towards improving the efficacy and the success rate. More researches needed to turn this enthusiasm into a grand clinical use.

References

1. Murray CJ, Lopez AD (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study *Lancet* 349: 1269-1276.
2. Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. *J Transl Med* 7: 97.
3. Broughton BR, Reutens DC, Sobey CG (2009) Apoptotic mechanisms after cerebral ischemia. *Stroke* 40: e331-339.
4. Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci* 22: 391-397.
5. Furlan AJ, Katzan IL, Caplan LR (2003) Thrombolytic Therapy in Acute Ischemic Stroke. *Curr Treat Options Cardiovasc Med* 5: 171-180.
6. Cheng Q, Zhang Z, Zhang S, Yang H, Zhang X, et al. (2015) Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. *Brain Res* 1594: 293-304.
7. Gu N, Rao C, Tian Y, Di Z, Liu Z, et al. (2014) Anti-inflammatory and antiapoptotic effects of mesenchymal stem cells transplantation in rat brain with cerebral ischemia. *J Stroke Cerebrovasc Dis* 23: 2598-2606.
8. Tang Y, Wang J, Lin X, Wang L, Shao B, et al. (2014) Neural stem cell protects aged rat brain from ischemia-reperfusion injury through neurogenesis and angiogenesis. *J Cereb Blood Flow Metab* 34: 1138-1147.
9. Wang L, Jiang F, Li Q, He X, Ma J, et al. (2014) Mild hypothermia combined with neural stem cell transplantation for hypoxic-ischemic encephalopathy: neuroprotective effects of combined therapy. *Neural Regen Res* 9: 1745-1752.
10. Kim JH, Lee J (2014) Induced neural stem cells protect neuronal cells against apoptosis. *Med Sci Monit* 20: 2759-2766.
11. Park KI, Teng YD, Snyder EY (2002) The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. *Nat Biotechnol* 20: 1111-1117.
12. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, et al. (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. *Nature* 422: 688-694.
13. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, et al. (2005) Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. *Nature* 436: 266-271.
14. Chen SH, Chang FM, Tsai YC, Huang KF, Lin CL, et al. (2006) Infusion of human umbilical cord blood cells protect against cerebral ischemia and damage during heatstroke in the rat. *Exp Neurol* 199: 67-76.
15. Zhang J, Li Y, Chen J, Yang M, Katakowski M, et al. (2004) Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells. *Brain Res* 1030: 19-27.
16. Einstein O, Fainstein N, Vaknin I, Mizrahi-Kol R, Reihartz E, et al. (2007) Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. *Ann Neurol* 61: 209-18.
17. Bacigaluppi M, Pluchino S, Martino G, Kilic E, Hermann DM (2008) Neural stem/precursor cells for the treatment of ischemic stroke. *J Neurol Sci* 265: 73-77.

18. Bühnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, et al. (2006) Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. *Brain* 129: 3238-3248.
19. Hosseini SM, Samimi N, Farahmandnia M, Shakibajahromi B, Sarvestani FS, et al. (2015) "The preventive effects of neural stem cells and mesenchymal stem cells intra-ventricular injection on brain stroke in rats." *North American Journal of Medical Sciences* 9: 390.
20. Hosseini SM, Farahmandnia M, Razi Z, Delavarifar S, Shakibajahromi B, et al. (2015) "Combination cell therapy with mesenchymal stem cells and neural stem cells for brain stroke in rats." *International journal of stem cells* 8.1: 99-105.
21. Hosseini SM, Farahmandnia M, Razi Z, Delavarifar S, Shakibajahromi B (2015) 12 hours after cerebral ischemia is the optimal time for bone marrow mesenchymal stem cell transplantation. *Neural regeneration research* 10: 904.
22. Haupt C, Witte OW, Frahm C (2007) Up-regulation of Connexin43 in the glial scar following photothrombotic ischemic injury. *Mol Cell Neurosci* 35: 89-99.
23. Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, et al. (2010) Inhibition of reactive astrocytes with fluorocitrate re- tards neurovascular remodeling and recovery after focal cerebral ischemia in mice. *J Cereb Blood Flow Metab* 30: 871-882.
24. Barreto GE, Sun X, Xu L, Giffard RG (2011) Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. *PLoS One* 6: e27881.
25. Bao Y, Qin L, Kim E, Bhosle S, Guo H, et al. (2012) CD36 is involved in astrocyte activation and astroglial scar formation. *J Cereb Blood Flow Metab* 32: 1567-1577.
26. Shimada IS, Borders A, Aronshtam A, Spees JL (2011) Proliferating reactive astrocytes are regulated by Notch-1 in the peri-infarct area after stroke. *Stroke* 42: 3231-3237.
27. Batrakova EV, Gendelman HE, Kabanov AV (2011) Cell-mediated drug delivery. *Expert Opin Drug Deliv* 8: 415-433.
28. Swanson RA, Ying W, Kauppinen TM (2004) Astrocyte influences on ischemic neuronal death. *Curr Mol Med* 4: 193-205.
29. Hosseini SM, Farahmandnia M, Kazemi S, Shakibajahromi B, Sarvestani FS, et al. (2015) A Novel Cell Therapy Method for Recovering after Brain Stroke in Rats. *Int J Stem Cells* 8: 191-199.